

Qian Jiang, M.D.



Peking University People's Hospital, Peking University Institute of Hematology

No. 11 Xizhimen South Street, Beijing, 100044, China.

Phone number: 86-10-66583802

Mobile: 86-13611115100

E-mail: jiangqian@medmail.com.cn

Medical Education

1984-1990, M.D. Peking University Health Science Center

Clinical History

2010 - Present, Chief Physician and Associate Professor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology;

2004 - 2010, Associate Chief Physician of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology;

1996 - 2004, Attending Doctor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology;

1990 - 1996, Resident Physician of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology.

Interests

Clinical research of CML, **lymphoma**, AML, ALL, CLL and MPN.

Research Experience

As a principle-investigator or sub-investigator in Peking University People's Hospital, Peking University Institute of Hematology:

2012 - Present, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence (Celgene);

2011 - Present, Nilotinib vs. imatinib clinical trial for newly-diagnosed CML patients (ENEST in China) (Novartis);

2008 - Present, as a sub-investigator, Dasatinib vs. imatinib clinical trial for newly-diagnosed CML patients (BMS);

2007 - Present, Dasatinib clinical trial for imatinib failure or intolerated CML patients (BMS);

2007 – 2010, An Open-Label, single arm study of bortezomib with CHOP in subjects with Relapsed or Refractory, diffuse large B-cell subtype of Non-Hodgkin's Lymphoma (Peking University People's Hospital and Xian-Janssen Pharmaceutical LTD.)

2006 – 2010, A Randomized, Open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non-Hodgkin's Lymphoma (Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)

2005 - 2008, AMN107 clinical trial for imatinib failure or intolerated CML patients (Novartis);

2001 - 2003, STI571 clinical trial for interferon failure or intolerated CML patients (Novartis).

Honors and Awards

2011 Outstanding Employee Award, Peking University People's Hospital

2009 The Best Doctor Award, The China Charity Federation

2007 Outstanding Employee Award, Peking University People's Hospital

Publications as the first author

1. **Jiang Q**, Zhao XJ, Qin YZ, Liu YR, Lai YY, Jiang B, Huang XJ. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia. *Am J Hematol* (In press).
2. **Jiang Q**, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. *Blood*. 2011 Mar 17;117(11):3032-40. Epub 2011 Jan 20.
3. **Jiang Q**, Jiang B, Chen SS, Jiang H, Qin YZ, Lai YY, et al. Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. *Zhonghua Xue Ye Xue Za Zhi*. 2012 Jan;33(1):6-9. Chinese.
4. **Jiang Q**, Chen SS, Jiang B, Jiang H, Qiu JY, Liu YR, et al. The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase. *Zhonghua Xue Ye Xue Za Zhi*. 2007 Nov;28(11):721-6. Chinese.
5. **Jiang Q**, Yang SM, Jiang B, Lu BB, Huang XJ, Wang DB. Diffuse alveolar hemorrhage as a complication in patients with hematologic malignancies after chemotherapy: report of two cases and literature review. *Zhonghua Xue Ye Xue Za Zhi*. 2007 Apr;28(4):230-4. Chinese.
6. **Jiang Q**, Chen SS, Jiang B, Jiang H, Qiu JY, Liu YR, et al. Efficacy and safety evaluation of imatinib mesylate for chronic myeloid leukemia in chronic phase: a 4.5-year follow-up of 100 cases. *Zhonghua Xue Ye Xue Za Zhi*. 2006 Nov;27(11):721-6. Chinese.
7. **Jiang Q**, Huang XJ, Liu KY, Chen H, Chen YH, Gao ZY, et al. Alterations in coagulation in patients during transplant conditioning regimen before allogeneic hematopoietic stem cell transplantation. *Zhonghua Xue Ye Xue Za Zhi*. 2006 Mar;27(3):173-7. Chinese.

8. **Jiang Q**, Liu KY, Huang XJ, Lu WK. Syndrome inappropriate ADH secretion after allogeneic hematopoietic stem cell transplantation: a case report and literature review. *Zhonghua Xue Ye Xue Za Zhi*. 2006 Feb;27(2):78-81. Chinese.
9. **Jiang Q**, Chen SS, Jiang B, Jiang H, Lu Y, Lu DP. Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions. *Beijing Da Xue Xue Bao*. 2005 Dec 18;37(6):612-5. Chinese.
10. **Jiang Q**, Huang XJ, Chen H, Xu LP, Liu DH, Chen YH, et al. Severe gastrointestinal bleeding after allogeneic hematopoietic stem cell transplantation--15 case analysis. *Zhonghua Xue Ye Xue Za Zhi*. 2005 May;26(5):277-80. Chinese.
11. **Jiang Q**, Chen SS, Jiang B, Jiang H, Lu Y, Qiu JY, et al. Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *Zhonghua Xue Ye Xue Za Zhi*. 2005 Jan;26(1):23-6. Chinese.
12. **Jiang Q**, Chen SS, Jiang B, Jiang H, Shi HL, Lu Y, et al. Bone marrow morphologic features in patients treated with imatinib for Philadelphia chromosome positive chronic myeloid leukemia. *Zhonghua Xue Ye Xue Za Zhi*. 2004 Mar;25(3):158-62. Chinese.
13. **Jiang Q**, Chen S, Jiang B, Jiang H, Lu Y, Huang X, et al. Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients. *Beijing Da Xue Xue Bao*. 2003 Apr 18;35(2):136-40. Chinese.

Selected Abstracts

1. **Jiang Q**, Xu LP, Liu DH, Liu KY, Jiang B, Zhang XH, et al. Imatinib mesylate is superior to allogeneic hematopoietic stem cell transplantation as the first-line therapy for patients with chronic myeloid leukemia in the early chronic phase. *Blood*. 2011; 118: Abstract #162.

Other Publications

1. Jiang H, Chen SS, Jiang B, **Jiang Q**, Qin YZ, Lai YY, et al. Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia. *Zhonghua Xue Ye Xue Za Zhi*. 2012 Feb;33(2):123-6. Chinese.
2. Qin Y, Chen S, Jiang B, **Jiang Q**, Jiang H, Li J, et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. *Ann Hematol*. 2011 Jan;90(1):47-52. Epub 2010 Aug 10.
3. Jiang H, Chen SS, Jiang B, **Jiang Q**, Qin YZ, Lai YY, et al. Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase. *Ann Hematol*. 2011 Jan;90(1):41-6. Epub 2010 Jul 29.
4. Qin YZ, Jiang B, **Jiang Q**, Zhang Y, Jiang H, Li JL, et al. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant. *Acta Haematol*. 2008;120(3):146-9. Epub 2008 Nov 28.
5. Zhu HH, Jiang B, Lu XJ, **Jiang Q**, Jiang H, Bao L, et al. The clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation. *Zhonghua Xue Ye Xue Za Zhi*. 2010 May;31(5):315-318. Chinese.
6. Qin Y, Jiang B, **Jiang Q**, Jiang H, Li J, Zhang Y, et al. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. *Ann Hematol*. 2009 Jan;88(1):37-41. Epub 2008 Jul 24.
7. Zhang XH, Hu Y, Bao L, **Jiang Q**, Yang LH, Lu XJ, et al. Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia. *Chin Med J (Engl)*. 2009 Sep 5;122(17):1969-73.
8. Lu J, Jiang H, **Jiang Q**, Bao L, Lu XJ, Zhang Y, et al. Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracycline based protocol. *Zhonghua Yi Xue Za Zhi*. 2008 Aug 19;88(32):2254-7. Chinese.

9. Zhang Y, **Jiang Q**, Qiu JY, Chen SS, Jiang B, Huang XJ. The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment. *Zhonghua Nei Ke Za Zhi*. 2007 Aug;46(8):648-50. Chinese.
10. Qin YZ, Liu YR, Li JL, Ruan GR, Zhu HH, **Jiang Q**, et al. Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients. *Zhonghua Yi Xue Za Zhi*. 2005 Nov 30;85(45):3186-9. Chinese.
11. Huang XJ, **Jiang Q**, Chen H, Xu LP, Liu DH, Chen YH, et al. Methotrexate for treatment of graft versus host disease after allogeneic hematopoietic stem cell transplantation. *Zhonghua Yi Xue Za Zhi*. 2005 Apr 27;85(16):1097-101. Chinese.
12. Huang XJ, Liu DH, Xu LP, Han W, **Jiang Q**, Chen YH, et al. Multiple factors in erythrocytic recovery following ABO-incompatible allogeneic HSCT. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2004 Dec;12(6):812-5. Chinese.
13. Jiang H, Chen SS, Jiang B, **Jiang Q**, Lu DP. Treatment of 54 chronic myelogenous leukemia with Gleevec. *Zhonghua Xue Ye Xue Za Zhi*. 2003 Jun;24(6):281-5. Chinese.